Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.41 |
| ▸ | CCR5 | P51681 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 1/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418641 | 0.78 | GPR119 (0.46) | C5AR1 | |
| SCHEMBL4634827 | 0.76 | C5AR1 (0.43) | C5AR1CCR5SIGMAR1CNR2UBE2M | |
| SCHEMBL4634472 | 0.73 | SLC6A4 (0.61) | — | |
| Hydrochloric Acid SCHEMBL4666549 | 0.72 | SLC6A4 (0.60) | — | |
| SCHEMBL6419540 | 0.70 | SLC6A4 (0.44) | PTGDR2 | |
| SCHEMBL6418851 | 0.69 | LMNA (0.48) | TRPM8UBE2MDCUN1D1 | |
| SCHEMBL10724404 | 0.68 | TRPM8 (0.55) | TRPM8C5AR1 | |
| SCHEMBL2966617 | 0.68 | UBE2M (0.54) | UBE2MDCUN1D1 | |
| SCHEMBL4965602 | 0.66 | KDM4E (0.43) | TRPM8UBE2MDCUN1D1 | |
| SCHEMBL6415646 | 0.66 | ALDH1A1 (0.40) | TRPM8C5AR1UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014789-A1 | Amide derivatives as selective serotonin re-uptake inhibitors | SLC6A4, HTR3C, HTR3A | TRPM8 1237/4885C5AR1 383/4885CCR5 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.